2020
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
Kaley TJ, Panageas KS, Pentsova EI, Mellinghoff IK, Nolan C, Gavrilovic I, DeAngelis LM, Abrey LE, Holland EC, Omuro A, Lacouture ME, Ludwig E, Lassman AB. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. Annals Of Clinical And Translational Neurology 2020, 7: 429-436. PMID: 32293798, PMCID: PMC7187704, DOI: 10.1002/acn3.51009.Peer-Reviewed Original ResearchConceptsRecurrent malignant gliomaDose-limiting toxicityMTOR inhibitor temsirolimusMalignant gliomasAkt inhibitor perifosinePhase I clinical trialDose level 3Dose level 7Phase II doseSynergistic anti-tumor effectKarnofsky performance statusPhase I trialDeadly primary brain cancerPI3K/Akt/mTOR axisPrimary brain cancerAkt/mTOR axisAnti-tumor effectsPotential therapeutic targetMost malignant gliomasPrior therapyTemsirolimus dosePerformance statusI trialIntracerebral hemorrhageCombined therapy
2015
Multicenter Phase I Dose Escalation Study of Hypofractionated Stereotactic Radiotherapy with Bevacizumab in the Treatment of Recurrent Malignant Glioma (S43.005)
Neil E, Clarke J, Beal K, Gutin P, Igor B, Kaley T, Lassman A, Perezic-Mustafa M, Young R, Omuro A. Multicenter Phase I Dose Escalation Study of Hypofractionated Stereotactic Radiotherapy with Bevacizumab in the Treatment of Recurrent Malignant Glioma (S43.005). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.s43.005.Peer-Reviewed Original Research
2014
AT-35INTERMITTENT HIGH DOSE (PULSATILE) ERLOTINIB FOR EGFRvIII MUTANT RECURRENT MALIGNANT GLIOMAS: A PILOT CLINICAL TRIAL
Lassman A, Grommes C, Panageas K, Iwamoto F, DeAngelis L, Kaley T, Gavrilovic I, Pentsova E, Omuro A, Corpuz C, Briggs S, Otap D, Qin W, Cross J, Mellinghoff I. AT-35INTERMITTENT HIGH DOSE (PULSATILE) ERLOTINIB FOR EGFRvIII MUTANT RECURRENT MALIGNANT GLIOMAS: A PILOT CLINICAL TRIAL. Neuro-Oncology 2014, 16: v16-v16. PMCID: PMC4217814, DOI: 10.1093/neuonc/nou237.35.Peer-Reviewed Original ResearchRecurrent malignant gliomaMalignant gliomasInhibitor therapyHigh-dose erlotinibOngoing complete responseEGFR-TKI erlotinibPopulation of patientsMedian age 58Pilot clinical trialInadequate drug deliveryKinase inhibitor therapyDose erlotinibEligible patientsPulsatile dosingAdverse eventsMedian survivalComplete responseDaily doseTKI erlotinibMedian CmaxAnaplastic gliomasClinical trialsAge 58Surgical armLimited efficacyPhase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways.
Omuro A, Kaley T, Pentsova E, DeAngelis L, Urba W, Taylor M, Anderson B, Gorman G, McLean S, Karmali R. Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways. Journal Of Clinical Oncology 2014, 32: 2071-2071. DOI: 10.1200/jco.2014.32.15_suppl.2071.Peer-Reviewed Original Research
2013
Phase I trial of temsirolimus (TEM) and perifosine (PER) for recurrent or progressive malignant glioma (MG).
Kaley T, Pentsova E, Omuro A, Mellinghoff I, Nolan C, Gavrilovic I, DeAngelis L, Lacouture M, Holland E, Lassman A. Phase I trial of temsirolimus (TEM) and perifosine (PER) for recurrent or progressive malignant glioma (MG). Journal Of Clinical Oncology 2013, 31: 2095-2095. DOI: 10.1200/jco.2013.31.15_suppl.2095.Peer-Reviewed Original ResearchRecurrent malignant gliomaPhase I trialMalignant gliomasI trialDose level 3Dose level 7Dose of temsirolimusMedian age 52Progressive malignant gliomaSynergistic anti-tumor effectPI3K/Akt/mTOR signalingAkt/mTOR SignalingMTOR inhibitor temsirolimusAnti-tumor effectsPotential therapeutic targetKPS 80Prior RTPrior therapyLimiting toxicitiesIntracerebral hemorrhageCombined therapyCombination therapyPreclinical dataLung infectionCell cycle arrest
2012
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-Oncology 2012, 15: 242-250. PMID: 23243055, PMCID: PMC3548585, DOI: 10.1093/neuonc/nos295.Peer-Reviewed Original ResearchConceptsKarnofsky performance scoreProgression-free survival ratesBevacizumab-naive patientsRecurrent malignant gliomaPhase II trialMalignant gliomasII trialPrimary endpointSurvival rateContinuous low-dose temozolomideMedian Karnofsky performance scoreLow Karnofsky performance scoreAdvanced malignant gliomaLow-dose temozolomideMedian overall survivalHalf of patientsFurther treatment strategiesMutations of EGFRBevacizumab exposureEligible patientsTemozolomide schedulesMG patientsOverall survivalMedian ageClinical benefit
2010
Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV).
Khasraw M, Abrey L, Lassman A, Hormigo A, Nolan C, Gavrilovic I, Mellinghoff I, Reiner A, DeAngelis L, Omuro A. Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV). Journal Of Clinical Oncology 2010, 28: 2065-2065. DOI: 10.1200/jco.2010.28.15_suppl.2065.Peer-Reviewed Original Research
2009
Antiangiogenic Strategies for the Treatment of Gliomas
Bazzoli E, Omuro A. Antiangiogenic Strategies for the Treatment of Gliomas. 2009, 243-263. DOI: 10.1007/978-1-4419-0410-2_12.Peer-Reviewed Original ResearchMalignant gliomasAntiangiogenic strategiesVascular endothelial growth factor (VEGF) pathwayEndothelial growth factor pathwayNew antiangiogenic treatmentsRecurrent malignant gliomaProgression-free survivalVEGF monoclonal antibodyInitial clinical benefitTreatment of gliomaHigh response rateGrowth factor pathwaysDifferent molecular driversMost patientsSurvival benefitClinical benefitAntiangiogenic treatmentAntiangiogenic drugsAntiangiogenesis treatmentResponse rateSolid tumorsComplex biologic processClinical settingFactor pathwayGliomas
2007
Editorial: what is new in the treatment of gliomas?
Omuro AM, Delattre JY. Editorial: what is new in the treatment of gliomas? Current Opinion In Neurology 2007, 20: 704-707. PMID: 17992093, DOI: 10.1097/wco.0b013e3282f1beef.Peer-Reviewed Original ResearchConceptsTreatment of gliomaTherapeutic decisionsEvidence-based therapeutic decisionsBevacizumab-based combinationsRecurrent malignant gliomaRole of chemotherapyPhase II trialStandard of carePhase III evidenceHigh response ratePhase II resultsSingle positive resultTemozolomide concomitantTemozolomide schedulesII trialSurvival benefitRandomized trialsGrade IIIMalignant gliomasResponse rateGliomasSuch trialsTraditional treatmentTrialsCodeletion status